BioNTech Announces Fourth Quarter and Full Year 2022 Financial …
WEBFourth Quarter 2022 Oncology Pipeline Update and Outlook. In 2022, BioNTech started five first-in-human clinical trials: BNT116, a FixVac program for non-small cell lung cancer (NSCLC), BNT141 and BNT142, two RiboMabs for CLDN18.2-positive and CLDN6-positive solid tumors and
Pfizer and BioNTech Advance Next-Generation COVID-19 …
WEBNov 16, 2022 · NEW YORK and MAINZ, GERMANY, NOVEMBER 16, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a Phase 1 study to evaluate the safety, tolerability and immunogenicity of a next generation COVID-19 vaccine candidate that aims to enhance SARS-CoV-2 T cell responses and potentially ...
The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you …
WEBAug 18, 2022 · This article provides a summary of the interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19 issued by WHO Strategic Advisory Group of Experts on Immunization (SAGE).
BioNTech Announces Third Quarter 2022 Financial Results and …
WEBNov 7, 2022 · BioNTech raises the lower end of its 2022 full year financial guidance to include estimated COVID-19 vaccine revenue of €16 - 17 billion. Conference call and webcast scheduled for November 7,...
Pfizer and BioNTech Announce New Agreement with U.S.
WEBOn June 25, 2022, Pfizer and BioNTech reported pivotal data demonstrating the safety, tolerability and immunogenicity of two Omicron-adapted vaccine candidates. These data have been shared...
BioNTech Announces Fourth Quarter and Full Year 2021
WEBMAINZ, Germany, March 30, 2022 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for the three months and full year ended December...
BioNTech to Report Third Quarter 2022 Financial Results and …
WEBMainz, Germany, October 24, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2022 on Monday, November 7 th, 2022.
Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5 …
WEBNov 18, 2022 · One month after a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibody titers against emerging Omicron sublineages increased 3.2- to 4.8-fold compared to the …
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for …
WEBDec 9, 2022 · NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for their mRNA-based combination vaccine candidate for influenza and COVID-19, which aims to help prevent two respiratory ...
BioNTech SE (NASDAQ:BNTX) Q4 2022 Earnings Call Transcript
WEBMar 30, 2023 · In December 2022, BioNTech and Fosun Pharma received full regulatory approval of our 30-microgram original COVID-19 vaccine as well as of 30-microgram booster dose of our original Omicron BA.5...
Skip to content